---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-004128"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-08-13T21:06:26+00:00"
generated_at: "2026-08-13T21:08:17.326692+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silexion restates FY2025 financials for 1-for-10 reverse split; auditor flags going concern

## Summary
- FY2025 net loss $11.9M vs $16.5M in 2024; operating loss $11.6M vs $12.6M.
- Cash and equivalents $5.99M at Dec 31, 2025, up from $1.19M; total assets $7.2M.
- Auditor expresses substantial doubt about ability to continue as going concern due to recurring losses.
- 1-for-10 reverse split effective May 28, 2026; all share and per-share data retroactively adjusted.
- R&D spend rose to $7.1M from $5.8M; G&A fell to $4.5M from $6.8M.

## SEC filing metadata
- accession: 0001178913-26-004128
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-08-13T21:06:26+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004128/0001178913-26-004128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004128/zk2635957.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-004128
- JSON: https://secwatch.observer/filing/0001178913-26-004128.json
- Plain text: https://secwatch.observer/filing/0001178913-26-004128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.